An observational study in Amyotrophic Lateral Sclerosis, sponsored by Technische Universität Dresden. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by Technische Universität Dresden · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 7 that started in 2022, is one of 13 observational ones, reaches primary completion later than 3 of the 25 other live ones, and was the 64th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:
Ambulanzpartner Soziotechnologie APST GmbH · Sites in Germany
Trace Neuroscience, Inc. · Sites in Germany, Netherlands, United Kingdom
Ages 18–75
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Leal Therapeutics, Inc · Sites in Germany, Italy, Netherlands and 1 more country
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 29 · Phase 3 25
First in 2003; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 219 across the 63 interventional studies, 200 across the 13 observational. Of the 48 that completed or were terminated, 23 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 76 have an industry lead sponsor. The 10 most frequent:
Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.
Technische Universität Dresden has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
| NCT06605612LMU KlinikumDevelopment and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | 2027-08-01 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The progressive loss of physical functioning resulting from ALS leads also to high psychosocial burden for those affected, and organizational challenges related to medical care and aids. A multidimensional and -professional care is advised in order to meet the complex requirements of this disease. In Germany, medical care structures may not fulfil these high requirements, since non-medical services such as psychological support or social counselling are not regularly included in care procedures for ALS patients. Specialised palliative care is not a standard and still commonly restricted to the last weeks of life. Additionally, it is well known that caregivers of ALS patients are highly burdened, but there is a lack of support services for them.
By means of a cross-sectional, multicentre survey, we aim to investigate patients' and caregivers' perception of medical care for ALS, provided in Germany - with particular regard to psychosocial and palliative aspects. The extent to which physical, psychological, social, spiritual, practical and informational needs are subjectively met will be assessed and correlations with mental wellbeing, subjective quality of life, attitudes towards life-sustaining measures and physician-assisted suicide, as well as caregiver burden will be examined.
Currently, study planning (questionnaires and ethical approval) is already completed and recruitment was started. The study aims to recruit 500 participants from nationwide ALS-centres. Cooperating ALS-centres will be recruited via the German Network for Motoneuron Diseases (MND-Net), of which our centre is a member. It is intended to provide data-based starting points on how care of ALS patients and their caregivers can be improved in Germany, in line with their needs.
patients with Amyotrophic Lateral Sclerosis and their caregivers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients' satisfaction with professional care
patients' satisfaction with professional care for potential symptoms in the six domains physical, psychological, social, spiritual, practical and informational
Time frame: baseline
subjective quality of life
McGill QoL
Time frame: baseline
mental wellbeing
HADS
Time frame: baseline
caregiver burden
CBI
Time frame: baseline
attitudes towards life-sustaining measures and assisted suicide
Time frame: baseline
Plan to share: Undecided — Upon reasonable request including a methodologically sound proposal for the usage of data approved by the responsible review committee, data may be shared.
Started Aug 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.
Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 28 months is below that.
Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Technische Universität Dresden →